David A. Siegel Shattuck Labs, Inc. Transaction History

Two Sigma Advisers, LP

$47 Billion
Q3 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Shattuck Labs, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 112,677 shares of STTK stock, worth $220,846. This represents 0.0% of its overall portfolio holdings.

Number of Shares

112,677

Previous 14,000 704.84%

Holding current value

$220,846

Previous $11,000 2281.82%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$0.73 - $2.45 $72,034 - $241,758	98,677 Added 704.84%	112,677 $262,000
Q2 2025 Aug 14, 2025	SELL	$0.73 - $1.3 $53,363 - $95,030	-73,100 Reduced 83.93%	14,000 $11,000
Q1 2025 May 15, 2025	SELL	$0.95 - $1.91 $102,600 - $206,280	-108,000 Reduced 55.36%	87,100 $82,000
Q4 2024 Feb 14, 2025	SELL	$1.0 - $1.92 $58,800 - $112,896	-58,800 Reduced 23.16%	195,100 $236,000
Q3 2024 Nov 14, 2024	BUY	$3.0 - $4.85 $653,100 - $1.06 Million	217,700 Added 601.38%	253,900 $886,000

Q2 2024 Aug 14, 2024	BUY	$3.56 - $11.18 $13,884 - $43,602	3,900 Added 12.07%	36,200 $139,000
Q1 2024 May 15, 2024	BUY	$7.37 - $10.09 $238,051 - $325,907	32,300 New	32,300 $288,000
Q3 2022 Nov 14, 2022	SELL	$2.6 - $5.52 $37,700 - $80,040	-14,500 Reduced 35.54%	26,300 $71,000
Q2 2022 Aug 15, 2022	SELL	$2.7 - $4.59 $119,340 - $202,878	-44,200 Reduced 52.0%	40,800 $166,000
Q1 2022 May 16, 2022	BUY	$4.22 - $8.89 $178,506 - $376,047	42,300 Added 99.06%	85,000 $362,000
Q4 2021 Feb 14, 2022	BUY	$8.36 - $21.08 $356,972 - $900,115	42,700 New	42,700 $363,000

Others Institutions Holding STTK

# of Institutions

Shares Held

38.6M

Call Options Held

22.2K

Put Options Held

View Full List

About Shattuck Labs, Inc.

Ticker STTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,382,000
Market Cap $83.1M
Description
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is ...

More about STTK

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account